SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending after a mixed earnings report, where it surpassed revenue and EPS expectations but provided a diverging outlook with increased revenue guidance alongside a lowered EPS forecast. The community is actively debating the market's reaction, with many viewing the dip as an attractive buying opportunity while others question the impact of acquisitions and long-term profitability amidst strong top-line growth.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending as its stock price significantly declines, with the community widely discussing its drop below its initial SPAC price, fueling predominantly bearish sentiment and intense debate over its valuation and ties to political controversies.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after receiving FDA Fast Track designation for its sonelokimab in PPP, with anticipation building for its upcoming Investor Day and significant clinical data updates across multiple inflammatory disease indications. The community widely views the stock as "extremely undervalued" given the nanobody drug's "best-in-class" potential, leading to persistent buyout speculation and investor frustration over current price volatility.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space (FJET) is trending as its IPO quiet period concludes and investors await potential news regarding an FAA Space Launch license, fueling community debate over its tiny float and high short interest, particularly amidst broader speculation for the upcoming Space X IPO.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

ATOM is trending with extraordinary volume after its recent earnings call, where management expressed high confidence in securing near-term licensing and commercial agreements for its MST technology in next-gen chips crucial for AI, sparking both bullish excitement for a valuation reset and skepticism among those wary of past unmet promises.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending after announcing positive topline Phase 3 data for AXPAXLI, demonstrating superiority over Eylea for wet AMD with fewer injections, sparking investor debate about its commercial dominance and heightened buyout speculation despite an initial stock dip.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is trending following its NYSE debut and SPAC merger today, with the community enthusiastically discussing its advanced neutral-atom quantum technology, significant partnerships with NASA and NVIDIA, and immediate revenue streams, positioning it as a potentially undervalued leader in the transformative quantum sector.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending following positive Phase 3 trial results for its COMP360 psilocybin therapy in treatment-resistant depression, with the community highlighting its strong efficacy and potential as a first-to-market solution in the evolving psychedelic therapeutics sector. This is further fueled by accelerated commercialization plans and FDA clearance for PTSD trials, sparking significant bullish sentiment and talks of short squeezes.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM Integrated Shipping Services is buzzing after news of a $4.2 billion all-cash acquisition by Hapag-Lloyd at $35 per share, sparking debates among investors about the deal's regulatory hurdles, potential for a short squeeze, and the continuation of dividends until its expected late 2026 close.

Cadence Design Systems, Inc. engages in the provision of design and development of integrated circuits and electronic devices. It operates through the following geographical segments: Americas, Asia, EMEA, and Japan. The company was founded by Alberto Sangiovanni-Vincentelli, Gudmundur A. Hjartarson, K. Bobby Chao, and K. Charles Janac in June 1988 and is headquartered in San Jose, CA.

Cadence Design Systems, Inc.

Cadence Design Systems is trending following strong Q4 earnings that surpassed estimates and an encouraging FY26 outlook, driven by robust demand for its AI-driven product portfolio and a record backlog. The community is actively discussing its pivotal role in semiconductor design for the AI era, while also debating its current valuation and potential for further growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SRRK UBS initiates Scholar Rock stock with Buy rating, sets $60 price target.
Key Investment Thesis:
 ∙ UBS views SR as a differentiated rare-disease biotech company with “pipeline-in-a-product potential,” particularly highlighting its lead candidate apitegromab 
Valuation Rationale:
 ∙ UBS believes SR stock remains undervalued due to regulatory delays and what it describes as underappreciated blockbuster potential for apitegromab, with opportunities for substantial long-term growth 
This is notably the highest price target among analysts covering the stock, with most other firms setting targets in the $42-$53 range. The company is working through regulatory challenges related to manufacturing issues and plans a U.S. launch in 2026 pending FDA approval

R.W.

StockTwits for iOS

Scholar Rock Holding Corp

 UBS initiates Scholar Rock stock with Buy rating, sets $60 price target.
Key Investment Thesis:
 ∙ UBS views SR as a differentiated rare-disease biotech company with “pipeline-in-a-product potential,” particularly highlighting its lead candidate apitegromab 
Valuation Rationale:
 ∙ UBS believes SR stock remains undervalued due to regulatory delays and what it describes as underappreciated blockbuster potential for apitegromab, with opportunities for substantial long-term growth 
This is notably the highest price target among analysts covering the stock, with most other firms setting targets in the $42-$53 range. The company is working through regulatory challenges related to manufacturing issues and plans a U.S. launch in 2026 pending FDA approval